Company Overview of Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat liver disease, inflammation, fibrosis, and HIV. Its lead product candidate includes cenicriviroc, an immunomodulator and dual inhibitor of CCR2 and CCR5, which is in Phase 2a study for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis disease; and Phase 2b study for HIV. The company was founded in 2006 and is headquartered in South San Francisco, California.
701 Gateway Boulevard
South San Francisco, CA 94080
Founded in 2006
Key Executives for Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Tobira Therapeutics, Inc., please visit www.tobiratherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.